Published in Nat Rev Cancer on March 01, 2010
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Chemistry and biology of multicomponent reactions. Chem Rev (2012) 2.09
Spatial organization of transmembrane receptor signalling. EMBO J (2010) 2.03
A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2014) 2.01
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Eph/ephrin molecules--a hub for signaling and endocytosis. Genes Dev (2010) 1.64
Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells. Circulation (2013) 1.61
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell (2012) 1.50
PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics (2011) 1.46
Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer (2012) 1.44
Protein kinase signaling networks in cancer. Curr Opin Genet Dev (2010) 1.41
Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol (2013) 1.33
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes (2013) 1.24
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov (2013) 1.22
Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One (2011) 1.22
Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr (2012) 1.18
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One (2012) 1.15
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene (2012) 1.12
Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol (2011) 1.11
In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics (2013) 1.11
Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One (2011) 1.09
EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene (2014) 1.08
Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol (2011) 1.08
Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal (2010) 1.08
Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. PLoS One (2013) 1.07
Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res (2010) 1.07
Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol (2011) 1.06
Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol (2016) 1.05
Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol (2014) 1.04
Contact repulsion controls the dispersion and final distribution of Cajal-Retzius cells. Neuron (2013) 1.03
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov (2014) 1.02
Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr (2012) 1.02
Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst (2012) 1.02
Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res (2012) 1.02
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther (2012) 1.01
Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry (2012) 1.01
Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One (2013) 1.00
HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol (2013) 1.00
EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene (2014) 1.00
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS One (2011) 1.00
Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol (2011) 1.00
Structurally encoded intraclass differences in EphA clusters drive distinct cell responses. Nat Struct Mol Biol (2013) 1.00
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem (2012) 1.00
EphA receptor signaling--complexity and emerging themes. Semin Cell Dev Biol (2011) 1.00
EphA/ephrin-A signaling is critically involved in region-specific apoptosis during early brain development. Cell Death Differ (2012) 0.99
Interplay between chemotaxis and contact inhibition of locomotion determines exploratory cell migration. Nat Commun (2015) 0.98
Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res (2012) 0.98
Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med (2012) 0.98
Ephrin-Eph signaling in embryonic tissue separation. Cell Adh Migr (2014) 0.98
Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry (2010) 0.97
Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1. Mol Biol Cell (2010) 0.97
Molecular mechanisms of tumor angiogenesis. Genes Cancer (2011) 0.96
Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. Carcinogenesis (2014) 0.96
Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment Cell Melanoma Res (2012) 0.96
PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. PLoS One (2011) 0.96
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
Eph/ephrin interactions modulate muscle satellite cell motility and patterning. Development (2011) 0.95
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS One (2013) 0.94
Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners. Sci Signal (2011) 0.93
Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J (2012) 0.93
Mutations in the EPHA2 gene are a major contributor to inherited cataracts in South-Eastern Australia. PLoS One (2013) 0.93
The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem (2011) 0.93
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta (2013) 0.93
SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol Cell Biol (2013) 0.93
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr (2012) 0.93
Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways. Neoplasia (2012) 0.92
Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Clin Pathol (2014) 0.91
EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis. PLoS Pathog (2015) 0.91
Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J Physiol (2011) 0.91
Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis. Am J Pathol (2011) 0.91
A chemical genetic approach reveals distinct EphB signaling mechanisms during brain development. Nat Neurosci (2012) 0.91
JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res (2014) 0.91
Regulation and misregulation of Eph/ephrin expression. Cell Adh Migr (2012) 0.91
Role of Eph/ephrin tyrosine kinase in malignant glioma. Neuro Oncol (2011) 0.90
copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. PLoS One (2013) 0.90
Molecular identification of venous progenitors in the dorsal aorta reveals an aortic origin for the cardinal vein in mammals. Development (2014) 0.90
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One (2013) 0.90
Ubiquitination switches EphA2 vesicular traffic from a continuous safeguard to a finite signalling mode. Nat Commun (2015) 0.89
EphrinA1-EphA2 signal induces compaction and polarization of Madin-Darby canine kidney cells by inactivating Ezrin through negative regulation of RhoA. J Biol Chem (2011) 0.89
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis (2013) 0.89
EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol (2013) 0.89
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. Oncotarget (2014) 0.89
Eph receptors as therapeutic targets in glioblastoma. Br J Cancer (2014) 0.88
Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines. Nano Lett (2013) 0.88
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer (2013) 0.87
Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer (2013) 0.87
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog (2013) 0.87
EphB6 receptor modulates micro RNA profile of breast carcinoma cells. PLoS One (2011) 0.87
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol (2012) 0.87
Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem (2012) 0.86
Roles of EphA2 in Development and Disease. Genes (Basel) (2013) 0.86
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell (2002) 8.08
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 7.14
Eph-ephrin bidirectional signaling in physiology and disease. Cell (2008) 7.12
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem (2008) 4.69
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Cell signaling in space and time: where proteins come together and when they're apart. Science (2009) 3.88
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell (2006) 3.51
EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell (2009) 3.40
Regulated cleavage of a contact-mediated axon repellent. Science (2000) 3.24
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res (2001) 3.24
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Identification and classification of p53-regulated genes. Proc Natl Acad Sci U S A (1999) 3.07
Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science (1995) 2.88
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol (2006) 2.87
Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci (2008) 2.85
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
EphB receptor activity suppresses colorectal cancer progression. Nature (2005) 2.84
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene (2000) 2.46
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell (2008) 2.40
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet (2007) 2.33
Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res (2001) 2.28
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci (2010) 2.17
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med (2007) 2.15
Eph/ephrin signaling: networks. Genes Dev (2008) 2.13
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A (2004) 2.01
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ (1999) 2.01
Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure (2006) 1.97
p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron (2008) 1.97
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res (2002) 1.96
EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene (2004) 1.95
Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science (2009) 1.91
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 1.83
EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet (2009) 1.82
Chromosomal abnormalities in cancer. N Engl J Med (2008) 1.81
Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem (2008) 1.80
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer (2007) 1.78
Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett (2008) 1.75
An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem (2002) 1.74
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res (2002) 1.70
Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell (2009) 1.68
Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood (2008) 1.66
Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer (2009) 1.65
Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res (2006) 1.64
Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J (2006) 1.62
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene (2005) 1.59
Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract. Proc Natl Acad Sci U S A (2008) 1.58
Paradoxes of the EphB4 receptor in cancer. Cancer Res (2007) 1.58
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res (2005) 1.57
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood (2005) 1.56
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets (2005) 1.54
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem (2004) 1.52
Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res (2007) 1.52
Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal (2004) 1.51
Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning. Nat Neurosci (2009) 1.50
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (2005) 1.49
Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci (2008) 1.48
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res (2003) 1.48
Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J Biol Chem (2003) 1.48
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J (2006) 1.48
EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem (2005) 1.46
Fluid shear stress induces arterial differentiation of endothelial progenitor cells. J Appl Physiol (1985) (2008) 1.46
Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis. Curr Biol (2003) 1.45
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets (2005) 1.44
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res (2004) 1.44
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res (2004) 1.43
Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene (2006) 1.43
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Overexpression confers an oncogenic potential upon the eph gene. Oncogene (1990) 1.43
EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol (2005) 1.41
Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem (2006) 1.41
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther (2006) 1.41
Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene (2008) 1.41
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene (2006) 1.39
EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res (2009) 1.39
Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res (2006) 1.38
EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood (2009) 1.38
Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol (2006) 1.37